New drug cocktail tested for patients out of options
NCT ID NCT03589222
Summary
This study is testing a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) for people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if this new combination can help control the cancer. About 62 patients who have already tried several other therapies will receive the treatment for as long as it works and they can tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universitaria de Navarra
Pamplona, Spain
-
Hospital 12 de Octubre
Madrid, Spain
-
Hospital Central de Asturias
Oviedo, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
-
Hospital Clinico de Madrid
Madrid, Spain
-
Hospital Dr Peset
Valencia, Spain
-
Hospital Germans Trials i Pujol
Badalona, Spain
-
Hospital ICO de Girona
Girona, Spain
-
Hospital ICO de L'hospitalet
L'Hospitalet de Llobregat, Spain
-
Hospital Morales Meseguer
Murcia, Spain
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Spain
-
Hospital Universitario de Donostia
San Sebastián, Spain
-
Hospital Universitario de Santiago
Santiago de Compostela, Spain
-
Hospital Virgen del Rocio
Seville, Spain
Conditions
Explore the condition pages connected to this study.